Alpha 2.0
Login Register
» Articles » PMID: 18831727

The Evolving Role of Oestrogen Receptor Beta in Clinical Breast Cancer

Overview
Journal Breast Cancer Res
Specialty Oncology
Date 2008 Oct 4
PMID 18831727
Citations 7
Authors
Valerie Speirs
Affiliations
Soon will be listed here.
Abstract

Controversy surrounds the potential clinical importance of oestrogen receptor (ER)beta in breast cancer, and three recent papers have sought to resolve this. In the present issue of Breast Cancer Research Novelli and colleagues explored the significance of ERbeta1 expression in 936 breast cancer patients, and they showed diverse relationships according to lymph node status. A second paper examined 442 breast cancers in which ERbeta1 was an independent predictor of recurrence, disease-free survival and overall survival. Finally a third paper showed that ERbeta2 was a powerful prognostic indicator in 757 breast cancers but this was dependent on cellular location, with nuclear ERbeta2 expression predicting good survival whilst cytoplasmic expression predicted worse outcome. These papers point to a clinical role for ERbeta in breast cancer and shall be discussed.

Citing Articles

Interaction between Estrogen Receptors and p53: A Broader Role for Tamoxifen?.

Das G, Oturkar C, Menon V Endocrinology. 2025; 166(3).

PMID: 39891710 PMC: 11837209. DOI: 10.1210/endocr/bqaf020.

Therapeutic Role of Tamoxifen for Triple-Negative Breast Cancer: Leveraging the Interaction Between ERβ and Mutant p53.

Scarpetti L, Oturkar C, Juric D, Shellock M, Malvarosa G, Post K Oncologist. 2023; 28(4):358-363.

PMID: 36772966 PMC: 10078911. DOI: 10.1093/oncolo/oyac281.

ERα-targeted endocrine therapy, resistance and the role of GPER.

Pepermans R, Prossnitz E Steroids. 2019; 152:108493.

PMID: 31518595 PMC: 6859199. DOI: 10.1016/j.steroids.2019.108493.

TP53 Status as a Determinant of Pro- vs Anti-Tumorigenic Effects of Estrogen Receptor-Beta in Breast Cancer.

Mukhopadhyay U, Oturkar C, Adams C, Wickramasekera N, Bansal S, Medisetty R J Natl Cancer Inst. 2019; 111(11):1202-1215.

PMID: 30990221 PMC: 6855950. DOI: 10.1093/jnci/djz051.

Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer.

Razandi M, Pedram A, Jordan V, Fuqua S, Levin E Oncogene. 2012; 32(27):3274-85.

PMID: 22907432 PMC: 3505272. DOI: 10.1038/onc.2012.335.

References
1.
Nakopoulou L, Lazaris A, Panayotopoulou E, Giannopoulou I, Givalos N, Markaki S . The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol. 2004; 57(5):523-8. PMC: 1770285. DOI: 10.1136/jcp.2003.008599. View
2.
JENSEN E, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S . Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci U S A. 2001; 98(26):15197-202. PMC: 65006. DOI: 10.1073/pnas.211556298. View
3.
Skliris G, Parkes A, Limer J, Burdall S, Carder P, Speirs V . Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, western blotting, and flow cytometry in human breast tissue. J Pathol. 2002; 197(2):155-62. DOI: 10.1002/path.1077. View
4.
Shaaban A, ONeill P, Davies M, Sibson R, West C, Smith P . Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol. 2003; 27(12):1502-12. DOI: 10.1097/00000478-200312000-00002. View
5.
Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R . A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res. 2008; 10(5):R74. PMC: 2614505. DOI: 10.1186/bcr2139. View